Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTREBIS vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DUTREBIS (fixed-dose combination of dapagliflozin and exenatide) combines a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist. Dapagliflozin inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Exenatide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reducing risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease (dapagliflozin component),Reducing risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors (dapagliflozin component)
Hypertension
Dutasteride 0.5 mg orally once daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal half-life of 8–10 hours in healthy adults, extended to 12–15 hours in moderate renal impairment (Cr Cl 30–59 m L/min); requires dose adjustment in severe renal impairment.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Dapagliflozin is primarily metabolized via uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) to an inactive metabolite. Exenatide is degraded by proteolytic degradation and eliminated via glomerular filtration with subsequent tubular reabsorption and metabolic catabolism.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Approximately 70% renal (mostly as unchanged drug via glomerular filtration and active tubular secretion), 20% fecal (via biliary excretion), and 10% metabolized with metabolites excreted equally.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
99% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Vd 12–15 L/kg, indicating extensive extravascular distribution and high tissue binding (primarily to erythrocytes and vascular smooth muscle).
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 45% (range 30–60%), due to incomplete absorption and first-pass metabolism. Food decreases rate but not extent.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No dose adjustment required for renal impairment. Dutasteride is not significantly renally eliminated.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment guidelines available.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not indicated in pediatric patients (<18 years). No established dosing.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment required based on age alone. Monitor for adverse effects, particularly dizziness and hypotension, in elderly patients.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Pancreatitis: Acute pancreatitis has been reported; discontinue if suspected,Diabetic ketoacidosis: SGLT2 inhibitors can cause ketoacidosis even with normal blood glucose levels,Volume depletion: May cause intravascular volume contraction and hypotension,Acute kidney injury: Monitor renal function,Hypoglycemia: Increased risk when used with insulin or insulin secretagogues,Severe gastrointestinal disease: Exenatide is not recommended in patients with severe gastrointestinal disease,Immunogenicity: Antibody formation to exenatide may occur
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
History of hypersensitivity to dapagliflozin, exenatide, or any excipients,Severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease (dapagliflozin component),Personal or family history of medullary thyroid carcinoma (exenatide component, based on animal studies),Patients with multiple endocrine neoplasia syndrome type 2 (exenatide component)
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Take with food to reduce tamsulosin absorption variability and decrease dizziness risk. Avoid grapefruit juice as it may increase tamsulosin levels via CYP3A4 inhibition. No other specific dietary restrictions.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
DUTREBIS (dutasteride and tamsulosin) is contraindicated in pregnancy. Dutasteride is a potent inhibitor of 5α-reductase, which can inhibit the conversion of testosterone to dihydrotestosterone (DHT). In animal studies, dutasteride caused feminization of male fetuses and impaired reproductive development. The risk is highest during the first trimester when sexual differentiation occurs. Tamsulosin, an alpha-1 adrenergic antagonist, is associated with fetal hypotension and hypoxia. No human data exist; both drugs should be avoided in pregnancy.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
DUTREBIS is contraindicated in breastfeeding. Dutasteride is excreted in human milk in animal studies; tamsulosin is excreted in rat milk. M/P ratio is unknown. Both drugs may cause adverse effects in the nursing infant, including hypotension and hormonal disruption.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
DUTREBIS is contraindicated in pregnancy and should not be used. No dose adjustments are applicable. Decreased drug clearance in pregnancy may theoretically increase exposure, but no data are available.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
DUTREBIS (dutasteride and tamsulosin) is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5-alpha-reductase inhibitor that reduces DHT levels, requiring 6 months for maximal effect. Tamsulosin is an alpha-1 blocker that provides rapid symptom relief within 2-4 weeks. Monitor for orthostatic hypotension, especially in elderly; titrate tamsulosin dose if needed. Check PSA levels before and during therapy; dutasteride reduces PSA by ~50%. Avoid in women, children, and patients with history of prostate cancer. Use with caution with strong CYP3A4 inhibitors (e.g., ketoconazole) due to increased tamsulosin exposure.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take the capsule 30 minutes after the same meal each day, preferably breakfast.,Do not crush, chew, or open the capsule; swallow whole.,Frequent ejaculation may reduce risk of retrograde ejaculation; inform if this occurs.,Rise slowly from lying or sitting to avoid dizziness or fainting.,Use effective contraception if partner is pregnant or may become pregnant; decomtamination in semen.,Report any breast lump, pain, or nipple discharge immediately.,Avoid driving until you know how the medication affects you; may cause dizziness.,Do not take with other alpha-blockers for prostate or blood pressure without doctor approval.,PSA levels will be reduced by half; inform your doctor of this effect.,Long-term treatment (6+ months) needed for maximal benefit on urinary symptoms.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTREBIS vs ALDORIL D30, answered by our medical review team.
DUTREBIS is a Antihypertensive Combination that works by DUTREBIS (fixed-dose combination of dapagliflozin and exenatide) combines a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist. Dapagliflozin inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. Exenatide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTREBIS and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTREBIS is: Dutasteride 0.5 mg orally once daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTREBIS and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTREBIS is classified as Category C. DUTREBIS (dutasteride and tamsulosin) is contraindicated in pregnancy. Dutasteride is a potent inhibitor of 5α-reductase, which can inhibit the conversion of testosterone to dihydr. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.